Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MK-7264 in Adults with Chronic Cough (PN030)
2017-003559-49Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic cough comparing MK-7264 with Placebo (2 arms). Primary endpoint: 24-hour coughs per hour at Week 24. Started Jan 2018; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on 2017-003559-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003559-49.